Teva settles patent litigation with AstraZeneca related to diabetes drug
The settlement allows Teva to commercialise its generic version of AstraZeneca's Byetta (exenatide injection) in the US beginning October 15, 2017
 "Teva settles patent litigation with AstraZeneca related to diabetes drug")
Teva Pharmaceuticals has settled the patent litigation with AstraZeneca related to AstraZeneca’s diabetes drug Byetta (exenatide) and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialise the generic version of Byetta in the US. Byetta (exenatide injection) is an injectable product used to treat type 2 diabetes.
The settlement allows Teva to commercialise its generic version of Byetta (exenatide injection) in the US beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.
The settlement allows Teva to commercialise its generic version of Byetta (exenatide injection) in the US beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.